Comparison of combination therapy with Atorvastatin and Carnitine versus Atorvastatin alone on lipid profile of hemodialized patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201604273742N3

Enrollment

Registered

2016-05-14

Start date

2016-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidaemia. Hyperlipidaemia, unspecified

Interventions

Intervention 1: In intervention group: Patients will receive 10 to 80 mg Atrovastatine daily based on primary lipid profile with 1000 mg Carnitine three times in a day for six months. Intervention 2:

Treatment - Drugs

In intervention group: Patients will receive 10 to 80 mg Atrovastatine daily based on primary lipid profile with 1000 mg Carnitine three times in a day for six months.

In control group: Patients will receive 10 to 80 mg Atrovastatine daily based on primary lipid profile for six months.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: hemodialized patients; age between 18 to 75 years old; informed consent form for participating in study. Exclusion criteria: using any medication which effect on lipid profile of patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Triglyceride. Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.;High density lipoprotein (HDL). Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.;Low density lipoprotein (LDL). Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.;Total cholesterol. Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.	—

Measure

Time frame

Triglyceride. Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.;High density lipoprotein (HDL). Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.;Low density lipoprotein (LDL). Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.;Total cholesterol. Timepoint: Beginning of study, first month, third month, 6th month. Method of measurement: milligrams per deciliter.

—

Secondary

Measure	Time frame
Adverse effects. Timepoint: First month, third month, 6th month. Method of measurement: History and clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Davoud Mohammadi Nejad

Tabriz University of Medical Sciences.

noshadh@tbzmed.ac.ir+98 41 3541 5023

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026